ESMO Congress | Conference

Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC

October 21st 2018

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.

Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

October 21st 2018

The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.

Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer

October 21st 2018

The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

OS Benefit Confirmed With Palbociclib Combo in Pretreated HR+/HER2- Breast Cancer

October 21st 2018

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.

RCC Gene Signatures Validated for Treatment Benefit

October 20th 2018

Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.

Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial

October 20th 2018

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Atezolizumab Combo Improves PFS in Frontline Metastatic TNBC

October 20th 2018

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

October 20th 2018

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

MET, EGFR C797S Linked With Acquired Resistance to Frontline Osimertinib in NSCLC

October 19th 2018

MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant non–small cell lung cancer.

Neutrophil to Lymphocyte Ratio Predicts Survival in Metastatic Melanoma

September 20th 2017

The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

September 20th 2017

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

Dr. Garassino on the PACIFIC Trial for NSCLC

September 20th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

Dr. Besse on the Combination of Treatments for NSCLC

September 20th 2017

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non

Dr. Bauml Discusses the FLAURA Study in NSCLC

September 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

Study Finds Hyperprogression After Immunotherapy in NSCLC Subset

September 14th 2017

Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

September 13th 2017

Nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Dr. West on the Significance of the PACIFIC Trial in NSCLC

September 13th 2017

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the significance of the PACIFIC trial in patients with non

Mixed Results for Pembrolizumab in Phase III HNSCC Study

September 13th 2017

Pembrolizumab (Keytruda) reduced the risk of death compared with standard of care therapy in patients with relapsed/metastatic head and neck squamous cell carcinoma, but the difference fell just shy of statistical significance.

Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCC

September 13th 2017

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).